Related Experiment Videos
Prompt versus preemptive intervention for EBV lymphoproliferative disease
Hans-Joachim Wagner1, Yee Chung Cheng, M Helen Huls
1Departments of Pediatrics and Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Blood
|January 31, 2004
Summary
Monitoring Epstein-Barr virus (EBV) DNA levels after hematopoietic stem cell transplantation (HSCT) can identify patients at risk for posttransplantation lymphoproliferative disorders (PTLD). Prompt treatment, rather than preemptive, is effective for PTLD management.
Area of Science:
- Immunology
- Virology
- Hematology
Background:
- Posttransplantation lymphoproliferative disorders (PTLD) are a serious complication after hematopoietic stem cell transplantation (HSCT).
- These disorders are driven by uncontrolled Epstein-Barr virus (EBV)-infected B cells.
- Elevated EBV DNA in peripheral blood mononuclear cells (PBMCs) can indicate PTLD risk.
Purpose of the Study:
- To evaluate the clinical utility of frequent EBV DNA monitoring for preemptive PTLD treatment in HSCT recipients.
- To determine if quantitative EBV DNA measurement aids in timely PTLD management.
Main Methods:
- Real-time quantitative polymerase chain reaction (RQ-PCR) was used to analyze over 1300 samples from 85 HSCT recipients.
- EBV DNA levels in PBMCs were quantified and monitored over time.
Main Results:
- No patient with consistently low EBV DNA levels developed PTLD.
- Nine patients experienced a single high EBV DNA load, and 16 had recurrent high loads.
- Only 8 patients with high EBV loads developed PTLD symptoms, all successfully treated promptly.
Conclusions:
- Quantitative EBV DNA measurement is valuable for identifying PTLD risk post-HSCT.
- Prompt treatment of PTLD, guided by EBV DNA levels, is effective.
- The findings support using EBV DNA monitoring for prompt, rather than preemptive, PTLD treatment.